Enoxaparin's half-life was drastically shortened from 5.26 hours to 0.897 hours during therapeutic plasma exchange, necessitating dose adjustments.
Does therapeutic plasma exchange affect the anti-factor Xa activity and half-life of enoxaparin?
Therapeutic plasma exchange dramatically shortens the half-life of enoxaparin, indicating that anti-factor Xa activity should be monitored and doses adjusted for patients undergoing TPE.
Abstract Purpose A case is reported in which the anti–factor Xa activity of enoxaparin was measured during therapeutic plasma exchange (TPE). Summary A 52-year-old male underwent TPE for antineutrophil cytoplasmic antibody–associated vasculitis while receiving therapeutic enoxaparin. Enoxaparin anti–factor Xa levels were measured before and immediately after TPE sessions as well as outside TPE sessions. The calculated enoxaparin half-life during TPE was 0.897 hours, whereas the calculated half-life outside TPE was 5.26 hours, demonstrating that the half-life of enoxaparin is dramatically shortened during TPE. Conclusion Enoxaparin’s anti–factor Xa activity should be monitored and dosing schedules should be adjusted to ensure therapeutic enoxaparin levels in all patients receiving TPE.
Hellwig et al. (2026) studied this question. Enoxaparin's half-life was drastically shortened from 5.26 hours to 0.897 hours during therapeutic plasma exchange, necessitating dose adjustments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: